AI and Big Data in Cancer: From Innovation to Impact, a new conference from Elsevier, a global information and analytics business specializing in science and health, will bring together experts from all aspects of cancer research and the digital medicine value chain to understand how to translate artificial intelligence and data-driven innovations into new clinical care practices for patients. These leaders, including 2018 Nobel laureate for Medicine, Dr. James Allison, will share pragmatic insights on finding the right partners to move innovations successfully forward. "It is time to shift our conversation from'what-technology-can-do' to'what-medicine-needs' and to raise awareness of what else is necessary to translate an AI-enabled and data-driven innovation into a marketed product," said Dr. Lynda Chin, Conference Chair, Founder and CEO of Apricity Health and Professor at Dell Medical School at the University of Texas, USA. "Understanding what these hurdles are is the first step to overcoming them. "The aim of this conference is to bring innovators together with stakeholders, from patients, clinicians and developers to regulators, payers and investors, so they can network and identify collaborators who can help them accelerate the translation of their innovation into clinical practices," Dr. Chin said. "Insights from the program's 40 key opinion leaders will advance the emerging digital medicine industry, building bridges from computer to clinics," said Laura Colantoni, Vice President for Reference Content, Elsevier, and one of the main organizers for the conference. "We are particularly excited about establishing this conference as a venue for successful innovators, influential facilitators, regulators and payers, as well as investors to find, engage and collaborate with clinicians, researchers and patients to accelerate progress in this area.

AI and Big Data in Cancer: From Innovation to Impact, a new conference from Elsevier, a global information and analytics business specializing in science and health, will bring together experts from all aspects of cancer research and the digital medicine value chain to understand how to translate artificial intelligence and data-driven innovations into new clinical care practices for patients. These leaders, including 2018 Nobel Laureate for Medicine, Dr. James Allison, will share pragmatic insights on finding the right partners to move innovations successfully forward. "It is time to shift our conversation from'what-technology-can-do' to'what-medicine-needs' and to raise awareness of what else is necessary to translate an AI-enabled and data-driven innovation into a marketed product," said Dr. Lynda Chin, Conference Chair, Founder and CEO of Apricity Health and Professor at Dell Medical School at the University of Texas, USA. "Understanding what these hurdles are is the first step to overcoming them. "The aim of this conference is to bring innovators together with stakeholders, from patients, clinicians and developers to regulators, payers and investors, so they can network and identify collaborators who can help them accelerate the translation of their innovation into clinical practices," Dr. Chin said. "Insights from the program's 40 key opinion leaders will advance the emerging digital medicine industry, building bridges from computer to clinics," said Laura Colantoni, Vice President for Reference Content, Elsevier, and one of the main organizers for the conference. "We are particularly excited about establishing this conference as a venue for successful innovators, influential facilitators, regulators and payers, as well as investors to find, engage and collaborate with clinicians, researchers and patients to accelerate progress in this area.